Literature DB >> 3971476

Comparison of the cellular pharmacology of doxorubicin in resistant and sensitive models of pancreatic cancer.

B K Chang, J A Gregory.   

Abstract

The cellular accumulation and retention of doxorubicin (ADR) was investigated in two models of pancreatic adenocarcinoma, which differ markedly in their sensitivity to ADR. In vitro studies revealed that the relatively resistant cell line, WD PaCa (or well-differentiated pancreatic adenocarcinoma of the Syrian hamster), actually had higher ADR cellular levels than the sensitive cell line, PD PaCa (or poorly differentiated pancreatic adenocarcinoma of the Syrian hamster). While the efflux of ADR from WD PaCa was greater, the overall retention of ADR by WD PaCa was comparable to PD PaCa. These results failed to document differences in accumulation or retention of ADR capable of explaining the difference in the sensitivity of the cell lines to ADR and indicate the need to search beyond attainable drug concentrations for mechanisms of primary ADR resistance.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3971476     DOI: 10.1007/bf00434351

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  18 in total

Review 1.  Chemotherapy of pancreatic cancer.

Authors:  F P Smith; P S Schein
Journal:  Semin Oncol       Date:  1979-09       Impact factor: 4.929

2.  Pharmacokinetics and metabolism of adriamycin in man.

Authors:  R S Benjamin; C E Riggs; N R Bachur
Journal:  Clin Pharmacol Ther       Date:  1973 Jul-Aug       Impact factor: 6.875

3.  Correlations between cytotoxicity, biochemical effects, drug levels, and therapeutic effectiveness of daunomycin and adriamycin on Sarcoma 180 ascites in mice.

Authors:  R Silvestrini; L Lenaz; G Di Fronzo; O Sanfilippo
Journal:  Cancer Res       Date:  1973-11       Impact factor: 12.701

4.  Tissue distribution and disposition of daunomycin (NCS-82151) in mice: fluorometric and isotopic methods.

Authors:  N R Bachur; A L Moore; J G Bernstein; A Liu
Journal:  Cancer Chemother Rep       Date:  1970-04

5.  In vitro uptake and cytotoxicity of adriamycin in primary and metastatic Lewis lung carcinoma.

Authors:  M G Donelli; B Barbieri; E Erba; M A Pacciarini; A Salmona; S Garattini; L Morasca
Journal:  Eur J Cancer       Date:  1979-09       Impact factor: 9.162

6.  Differential sensitivity of pancreatic adenocarcinoma cell lines to chemotherapeutic agents in culture.

Authors:  B K Chang
Journal:  Cancer Treat Rep       Date:  1983-04

7.  An animal model of pancreatic cancer involving whole pancreas transplantation.

Authors:  H J Sayers; D H Dail; M J Orloff
Journal:  Surg Forum       Date:  1978

8.  Early phase pharmacokinetics of doxorubicin (adriamycin) in plasma of cancer patients during single- or multiple-drug therapy.

Authors:  E Piazza; M G Donelli; M Broggini; C Sessa; N Natale; L Ottolenghi; S Marsoni; A Libretti; C Mangioni; L Morasca
Journal:  Cancer Treat Rep       Date:  1980 Aug-Sep

9.  Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice.

Authors:  T H Corbett; B J Roberts; W R Leopold; J C Peckham; L J Wilkoff; D P Griswold; F M Schabel
Journal:  Cancer Res       Date:  1984-02       Impact factor: 12.701

10.  Uptake of adriamycin and daunomycin in L1210 and human leukemia cells: a comparative study.

Authors:  D S Chervinsky; J J Wang
Journal:  J Med       Date:  1976
View more
  4 in total

1.  Effect of verapamil on doxorubicin activity and pharmacokinetics in mice bearing resistant and sensitive solid tumors.

Authors:  F Formelli; L Cleris; R Carsana
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

2.  Circumvention of drug resistance in human non-small cell lung cancer in vitro by verapamil.

Authors:  S Merry; E R Courtney; C A Fetherston; S B Kaye; R I Freshney
Journal:  Br J Cancer       Date:  1987-10       Impact factor: 7.640

3.  Resistance of human glioma to adriamycin in vitro: the role of membrane transport and its circumvention with verapamil.

Authors:  S Merry; C A Fetherston; S B Kaye; R I Freshney; J A Plumb
Journal:  Br J Cancer       Date:  1986-01       Impact factor: 7.640

4.  Role of the calmodulin inhibitor trifluoperazine on the induction and expression of cell cycle traverse perturbations and cytotoxicity of daunorubicin and doxorubicin (adriamycin) in doxorubicin-resistant P388 mouse leukaemia cells.

Authors:  R Ganapathi; A Yen; D Grabowski; H Schmidt; R Turinic; R Valenzuela
Journal:  Br J Cancer       Date:  1986-04       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.